Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Metformin for Newly Diagnosed T2DM with NAFLD
NCT03796975Phase 4Completed
- Sponsor
- Xijing Hospital
- Start
- Jun 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of pioglitazone in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Xijing Hospital. Primary endpoints: Decreased of liver fat content of fatty liver at 24 weeks, Change of B-cell function (homeostasis model assessment of insulin resistance index) at 24 weeks and 1 more. Started Jun 2018; status: completed.
02
Drugs
pioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03796975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796975.